Abstract
BackgroundDisease-modifying treatments for Huntington’s disease (HD) are entering clinical trials: there is a pressing need for objective outcome measures of disease progression. Our previous work showed an association between 2 novel, objective cognitive tasks and apathy - a core feature of disease progression in HD. ObjectiveEvaluate the longitudinal validity and sensitivity of the novel Persistence and Maze tasks to assess their utility as clinical outcome measures in HD. Methods83 participants positive for the HD gene and 54 controls performed a battery of established and novel tools, at baseline and 12 month follow up. ResultsThe Maze task was found to be the most sensitive measure of change at 12 months, including the current gold-standard measure (the composite disease progression score). ConclusionThe Maze task has potential as a novel outcome measure of disease progression in HD and may have utility in other major neurodegenerative diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.